News

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Figure 1 Magnetic resonance imaging (MRI) of the orbital tumor. The top left MRI image shows the tumor in the…

2 years ago

Healthy Extracts Launches First Anti-Aging Formulation, LONGEVITY

LONGEVITY Anti-Aging™ BERGAMET’s New LONGEVITY Anti-Aging™ LAS VEGAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a…

2 years ago

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…

2 years ago

Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of…

2 years ago

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

2 years ago

Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a…

2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A…

2 years ago

Portage Biotech Reports Business and Strategic Update

Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn.,…

2 years ago

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for…

2 years ago

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous…

2 years ago